Damora Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 19, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
(1)
For a list of the financial statements included herein, see Index to the Consolidated Financial Statements on page F-1 of this Annual Report on Form 10-K, incorporated into this Item by reference.
(2)
Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.
(3)
Exhibits
| ExhibitNumber | Exhibit Description | Incorporated by ReferenceHerein from Form or Schedule | Filing Date | SEC File / Reg. Number |
|---|---|---|---|---|
| 2.1† | Asset Purchase Agreement by and between the Registrant and Bridge Medicines LLC. | Form 8-K (Exhibit 2.1) | October 7, 2024 | 001-39655 |
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant. | Form 8-K (Exhibit 3.1) | November 4, 2020 | 001-39655 |
| 3.2 | Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant. | Form 8-K(Exhibit 3.1) | September 5, 2024 | 001-39655 |
| 3.3 | Certificate of Designation: Series A Non-Voting Convertible Preferred Stock. | Form 8-K (Exhibit 3.1) | October 7, 2024 | 001-39655 |
| 3.4 | Amended and Restated By-laws of the Registrant. | Form 8-K (Exhibit 3.2) | November 4, 2020 | 001-39655 |
| 3.5* | Certificate of Amendment to Amended and Restated By-laws of the Registrant. | |||
| 4.1 | Specimen Common Stock Certificate. | Form S-1/A(Exhibit 4.1) | October 22, 2020 | 333-249369 |
| 4.2* | Description of Capital Stock. | |||
| 10.1# | 2020 Stock Option and Grant Plan. | Form S-1/A(Exhibit 10.1) | October 22, 2020 | 333-249369 |
| 10.2# | 2020 Equity Incentive Plan, and forms of award agreements thereunder. | Form 10-K(Exhibit 10.2) | March 8, 2024 | 001-39655 |
| 10.3# | Senior Executive Cash Incentive Bonus Plan. | Form S-1/A(Exhibit 10.3) | October 22, 2020 | 333-249369 |
| 10.4# | Executive Separation Benefits Plan. | Form 8-K(Exhibit 10.1) | July 6, 2021 | 001-39655 |
| 10.5# | Form of Officer Indemnification Agreement between the Registrant and each of its executive officers. | Form S-1/A(Exhibit 10.4) | October 22, 2020 | 333-249369 |
| 10.6# | Form of Director Indemnification Agreement between the Registrant and each of its directors. | Form S-1/A(Exhibit 10.5) | October 22, 2020 | 333-249369 |
| 10.7* | Non-Employee Director Compensation Policy, as amended. | |||
| 10.8# | Service Agreement between Galecto Biotech ApS and Hans Schambye, dated April 23, 2013. | Form S-1/A(Exhibit 10.7) | October 22, 2020 | 333-249369 |
| 10.9#* | Retention Agreement between Galecto Biotech ApS and Hans Schambye, dated October 7, 2024. | |||
| 10.10# | Employment Agreement between Galecto, Inc. and Jonathan Freve, dated March 11, 2020. | Form S-1/A(Exhibit 10.12) | October 22, 2020 | 333-249369 |
| ExhibitNumber | Exhibit Description | Incorporated by ReferenceHerein from Form or Schedule | Filing Date | SEC File / Reg. Number |
|---|---|---|---|---|
| 10.11# | Amendment to Employment Agreement between Galecto, Inc. and Jonathan Freve, dated March 14, 2020. | Form S-1/A(Exhibit 10.13) | October 22, 2020 | 333-249369 |
| 10.12# | Employment Agreement between the Registrant and Garrett Winslow, dated April 12, 2021. | Form 10-Q(Exhibit 10.1) | August 12, 2024 | 001-39655 |
| 10.13#* | Retention Compensation Agreement between the Registrant and Garrett Winslow, dated October 7, 2024. | |||
| 10.14 | Form of Support Agreement. | Form 8-K(Exhibit 10.1) | October 7, 2024 | 001-39655 |
| 10.15+* | License Agreement between Bridge Medicines LLC and Rockefeller University, dated February 3, 2020. | |||
| 10.16* | English language summary of Lease Agreement between Galecto Biotech ApS and COBIS A/S, dated November 11, 2024. | |||
| 19.1* | Statement of Company Policy on Insider Trading and Disclosure. | |||
| 23.1* | Consent of EY Godkendt Revisionspar`tnerselskab, independent registered public accounting firm. | |||
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |||
| 31.2* | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |||
| 32.1** | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |||
| 101.INS | Inline XBRL Instance Document | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||
*Filed herewith.
** Furnished herewith. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange Act, except to the extent that we specifically incorporate it by reference.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.